Market Research Logo

Sleep Disorders Drug Development Pipeline Review, 2017

Sleep Disorders Drug Development Pipeline Review, 2017

Summary

Restless legs syndrome is characterized by a distressing, irresistible need or urge to move the legs. There are a total of eight products in development for this indication, by eight companies. Key companies operating in this pipeline space include Mundipharma International and Galenica.

Nocturia describes the excessive urination at night. There are a total of eight products in development for this indication, by six companies. Key companies operating in this pipeline space include Ferring International and Sanwa Kagaku Kenkyusho.

Finally, Insomnia is a serious sleeping disorder characterized by the inability to fall or stay asleep. There are a total of 31 products in development for this indication, by 27 companies and three academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Merck and Overseas Pharmaceuticals.

Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

The report,Sleep Disorders Drug Development Pipeline Review, 2017 provides an overview of the sleep disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for sleep disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Sleep Disorders Report Coverage
    • Restless Legs Syndrome – Overview
    • Nocturia – Overview
    • Insomnia – Overview
  • Therapeutics Development
    • Restless Legs Syndrome
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Restless Legs Syndrome
        • Table Number of Products under Development for Restless Legs Syndrome
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies Restless Legs Syndrome
        • Table Number of Products under Development by Companies Restless Legs Syndrome
      • Products under Development by Companies
        • Table Products under Development by Companies Restless Legs Syndrome
    • Nocturia
      • Pipeline Overview
        • Table Figure 3: Number of Products under Development for Nocturia
        • Table Number of Products under Development for Nocturia
      • Pipeline by Companies
        • Table Figure 4: Number of Products under Development by Companies Nocturia
        • Table Number of Products under Development by Companies Nocturia
      • Products under Development by Companies
        • Table Products under Development by Companies Nocturia
    • Insomnia
      • Pipeline Overview
        • Table Figure 5: Number of Products under Development for Insomnia
        • Table Number of Products under Development for Insomnia
      • Pipeline by Companies
        • Table Figure 6: Number of Products under Development by Companies Insomnia
        • Table Number of Products under Development by Companies Insomnia
      • Pipeline by Universities/Institutes
        • Table Figure 7: Number of Products under Development by Universities/Institutes Insomnia
        • Table Number of Products under Development by Universities/Institutes Insomnia
      • Products under Development by Companies
        • Table Products under Development by Companies Insomnia
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes Insomnia
  • Therapeutics Assessment
    • Restless Legs Syndrome
      • Assessment by Target
        • Table Figure 8: Number of Products by Targets Restless Legs Syndrome
        • Table Figure 9: Number of Products by Stage and Targets Restless Legs Syndrome
        • Table Number of Products by Stage and Target Restless Legs Syndrome
      • Assessment by Mechanism of Action
        • Table Figure 10: Number of Products by Mechanism of Actions Restless Legs Syndrome
        • Table Figure 11: Number of Products by Stage and Mechanism of Actions Restless Legs Syndrome
        • Table Number of Products by Stage and Mechanism of Action Restless Legs Syndrome
      • Assessment by Route of Administration
        • Table Figure 12: Number of Products by Routes of Administration Restless Legs Syndrome
        • Table Figure 13: Number of Products by Stage and Routes of Administration Restless Legs Syndrome
        • Table Number of Products by Stage and Route of Administration Restless Legs Syndrome
      • Assessment by Molecule Type
        • Table Figure 14: Number of Products by Molecule Types Restless Legs Syndrome
        • Table Figure 15: Number of Products by Stage and Molecule Types Restless Legs Syndrome
        • Table Number of Products by Stage and Molecule Type Restless Legs Syndrome
    • Nocturia
      • Assessment by Target
        • Table Figure 16: Number of Products by Targets Nocturia
        • Table Figure 17: Number of Products by Stage and Targets Nocturia
        • Table Number of Products by Stage and Target Nocturia
      • Assessment by Mechanism of Action
        • Table Figure 18: Number of Products by Mechanism of Actions Nocturia
        • Table Figure 19: Number of Products by Stage and Mechanism of Actions Nocturia
        • Table Number of Products by Stage and Mechanism of Action Nocturia
      • Assessment by Route of Administration
        • Table Figure 20: Number of Products by Routes of Administration Nocturia
        • Table Figure 21: Number of Products by Stage and Routes of Administration Nocturia
        • Table Number of Products by Stage and Route of Administration Nocturia
      • Assessment by Molecule Type
        • Table Figure 22: Number of Products by Molecule Types Nocturia
        • Table Figure 23: Number of Products by Stage and Molecule Types Nocturia
        • Table Number of Products by Stage and Molecule Type Nocturia
    • Insomnia
      • Assessment by Target
        • Table Figure 24: Number of Products by Top 10 Targets Insomnia
        • Table Figure 25: Number of Products by Stage and Top 10 Targets Insomnia
        • Table Number of Products by Stage and Target Insomnia
      • Assessment by Mechanism of Action
        • Table Figure 26: Number of Products by Top 10 Mechanism of Actions Insomnia
        • Table Figure 27: Number of Products by Stage and Top 10 Mechanism of Actions Insomnia
        • Table Number of Products by Stage and Mechanism of Action Insomnia
      • Assessment by Route of Administration
        • Table Figure 28: Number of Products by Routes of Administration Insomnia
        • Table Figure 29: Number of Products by Stage and Routes of Administration Insomnia
        • Table Number of Products by Stage and Route of Administration Insomnia
      • Assessment by Molecule Type
        • Table Figure 30: Number of Products by Stage and Molecule Types Insomnia
        • Table Number of Products by Stage and Molecule Type Insomnia
  • Companies Involved in Therapeutics Development
    • Restless Legs Syndrome
      • Galenica Ltd
        • Table Restless Legs Syndrome – Pipeline by Galenica Ltd
      • Hisamitsu Pharmaceutical Co Inc
        • Table Restless Legs Syndrome – Pipeline by Hisamitsu Pharmaceutical Co Inc
      • Merz Pharma GmbH & Co KgaA
        • Table Restless Legs Syndrome – Pipeline by Merz Pharma GmbH & Co KgaA
      • Mundipharma International Ltd
        • Table Restless Legs Syndrome – Pipeline by Mundipharma International Ltd
      • Omeros Corp
        • Table Restless Legs Syndrome – Pipeline by Omeros Corp
      • Serina Therapeutics Inc
        • Table Restless Legs Syndrome – Pipeline by Serina Therapeutics Inc
    • Nocturia
      • Astellas Pharma Inc
        • Table Nocturia – Pipeline by Astellas Pharma Inc
      • Ferring International Center SA
        • Table Nocturia – Pipeline by Ferring International Center SA
      • Sanwa Kagaku Kenkyusho Co Ltd
        • Table Nocturia – Pipeline by Sanwa Kagaku Kenkyusho Co Ltd
      • Vantia Therapeutics
        • Table Nocturia – Pipeline by Vantia Therapeutics
    • Insomnia
      • Alexza Pharmaceuticals Inc
        • Table Insomnia – Pipeline by Alexza Pharmaceuticals Inc
      • Athenex Inc
        • Table Insomnia – Pipeline by Athenex Inc
      • Eisai Co Ltd
        • Table Insomnia – Pipeline by Eisai Co Ltd
      • Evotec AG
        • Table Insomnia – Pipeline by Evotec AG
      • Grupo Ferrer Internacional SA
        • Table Insomnia – Pipeline by Grupo Ferrer Internacional SA
      • Heptares Therapeutics Ltd
        • Table Insomnia – Pipeline by Heptares Therapeutics Ltd
      • Idorsia Ltd
        • Table Insomnia – Pipeline by Idorsia Ltd
      • Intec Pharma Ltd
        • Table Insomnia – Pipeline by Intec Pharma Ltd
      • Intra-Cellular Therapies Inc
        • Table Insomnia – Pipeline by Intra-Cellular Therapies Inc
      • Johnson & Johnson
        • Table Insomnia – Pipeline by Johnson & Johnson
      • Leading BioSciences Inc
        • Table Insomnia – Pipeline by Leading BioSciences Inc
      • Merck & Co Inc
        • Table Insomnia – Pipeline by Merck & Co Inc
      • Neurim Pharmaceuticals Ltd
        • Table Insomnia – Pipeline by Neurim Pharmaceuticals Ltd
      • Reviva Pharmaceuticals Inc
        • Table Insomnia – Pipeline by Reviva Pharmaceuticals Inc
      • Shionogi & Co Ltd
        • Table Insomnia – Pipeline by Shionogi & Co Ltd
      • Taisho Pharmaceutical Holdings Co Ltd
        • Table Insomnia – Pipeline by Taisho Pharmaceutical Holdings Co Ltd
      • Yangtze River Pharmaceutical Group
        • Table Insomnia – Pipeline by Yangtze River Pharmaceutical Group
  • Dormant Projects
    • Restless Legs Syndrome
      • Table Restless Legs Syndrome – Dormant Projects
    • Nocturia
      • Table Nocturia – Dormant Projects
    • Insomnia
      • Table Insomnia – Dormant Projects
  • Discontinued Products
    • Restless Legs Syndrome
      • Table Restless Legs Syndrome – Discontinued Products
    • Insomnia
      • Table Insomnia – Discontinued Products
  • Product Development Milestones
    • Restless Legs Syndrome
      • Featured News & Press Releases
    • Nocturia
      • Featured News & Press Releases
    • Insomnia
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report